Running Out of Breath: The Diminishing Role of Gabapentinoids in Epilepsy

Affiliations

Comment

Samuel Lapalme-Remis. Epilepsy Curr. 2024.

. 2024 May 22;24(4):265-267.

doi: 10.1177/15357597241253505. eCollection 2024 Jul-Aug.

No abstract available

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Gabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary Disease : A Population-Based Cohort Study.
Rahman AA, Dell'Aniello S, Moodie EEM, Durand M, Coulombe J, Boivin JF, Suissa S, Ernst P, Renoux C. Rahman AA, et al. Ann Intern Med. 2024 Feb;177(2):144-154. doi: 10.7326/M23-0849. Epub 2024 Jan 16. Ann Intern Med. 2024. PMID: 38224592

1. Andrews CO, Fischer JH. Gabapentin: a new agent for the management of epilepsy. Ann Pharmacother. 1994;28(10):1188–1196. - PubMed
1. Marson AG, Al-Kharusi AM, Alwaidh M, et al. SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–1015. - PMC - PubMed
1. Rowan AJ, Ramsay RE, Collins JF, et al. VA Cooperative Study 428 Group. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64(11):1868–1873. - PubMed
1. Abou-Khalil BW. Update on antiseizure medications 2022. Continuum (Minneap Minn). 2022;28(2):500–535. - PubMed
1. Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2011;77(19):1752–1755. - PMC - PubMed